TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01392950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti
Description: Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Study: NCT00858871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
Study: NCT02147132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.
Study: NCT00858871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
Study: NCT03317509

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic (rTMS)
Description: Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
Study: NCT02147132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
Study: NCT03599440

Intervention type: OTHER
Intervention: Pressure line extensions
Description: Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line
Study: NCT02634528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Julphar Insulin N (human isophane insulin)
Description: investigational insulin: Julphar N (human isophane insulin), biosimilar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Basal (NPH, human isophane insulin)
Description: marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
Study: NCT04162977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted Interventions
Description: The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
Study: NCT00856453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home yoga practice
Description: training for and tracking of patient's practice of yoga at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home yoga practice
Description: training for and tracking of patient's practice of yoga at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga classes
Description: organized out of home classes for yoga
Study: NCT02147132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
Study: NCT02465866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Description: Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Description: Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicoprofen
Description: Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicoprofen
Description: Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet
Description: Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet
Description: Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
Study: NCT05038319

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EUS
Description: The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
Study: NCT02147132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
Study: NCT02732470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong
Description: The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
Study: NCT02326493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
Study: NCT03964272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Bilateral Subthalamotomy
Description: Exablate bilateral treatment for Parkinson's Disease Motor Features
Study: NCT02276937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DVC1-0101
Description: The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DVC1-0101
Description: The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DVC1-0101
Description: The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
Study: NCT02475707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiTAA-specific T cells
Description: The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart.
Study: NCT01946750

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Whole blood
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
Study: NCT03745209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
Study: NCT03062852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication safety vest
Description: The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention.
Study: NCT02992743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letetresgene autoleucel (GSK3377794)
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT00677066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Description: Administer oxygen at home or in hospital
Study: NCT02835794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study: NCT02835794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study: NCT03229902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mantra meditation
Description: see study description
Study: NCT03195946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: tablets for oral use, 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: syrup for oral use, 4mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail of CYP450 substrates
Description: Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
Study: NCT01809847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy.
Study: NCT01998165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
Study: NCT00931606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: up to 4 subcutaneous doses of sotatercept given once every 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 4 subcutaneous doses of placebo given once every 28 days
Study: NCT02750488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study: NCT03685227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Description: This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
Study: NCT00780416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: 750 mg every 8 hours for 12 weeks
Study: NCT00576940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reconvan
Description: isocaloric, immunomodulating entral diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptisorb
Description: isocaloric, isopeptic standard diet
Study: NCT01058707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules
Study: NCT02503215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Stockings
Description: To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
Study: NCT00678652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
Study: NCT02938819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-oriented upper-limb intervention
Description: The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
Study: NCT03203317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 2 h insulin clamp

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling exercise
Study: NCT02001987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
Study: NCT00780416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 48 weeks
Study: NCT03059147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF1126
Description: SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
Study: NCT02643238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort
Description: This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainPort
Description: This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
Study: NCT01793766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain modulation
Description: Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham modulation
Study: NCT00482625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo pancreatectomy
Study: NCT03059147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.